Cetrorelix Pamoate Intermittent Intramuscular (IM) Dosage Regimens in Patients With Symptomatic BPH: a 1 Year Placebo-controlled Efficacy Study and Long-term Safety Assessment
Phase of Trial: Phase III
Latest Information Update: 10 Aug 2018
At a glance
- Drugs Cetrorelix (Primary)
- Indications Benign prostatic hyperplasia
- Focus Registrational; Therapeutic Use
- Sponsors AEterna Zentaris Inc
- 18 Jan 2011 Additional trial locations (Bulgaria, Germany) identified as reported by ClinicalTrials.gov.
- 29 Dec 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 26 Aug 2009 Status changed from completed to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History